BackgroundPACAP and VIP are closely related neuropeptides with wide distribution and potent effect in the vasculature. We previously reported vasomotor activity in peripheral vasculature of male wild type (WT) and PACAP-deficient (KO) mice. However, female vascular responses are still unexplored. We hypothesized that PACAP-like activity is maintained in female PACAP KO mice and the mechanism through which it is regulated differs from that of male PACAP KO animals.MethodsWe investigated the vasomotor effects of VIP and PACAP isoforms and their selective blockers in WT and PACAP KO female mice in carotid and femoral arteries. The expression and level of different PACAP receptors in the vessels were measured by RT-PCR and Western blot.ResultsI...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
BACKGROUND: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (...
BACKGROUND: PACAP and VIP are closely related neuropeptides with wide distribution and potent effect...
PACAP and VIP are closely related neuropeptides with wide distribution and potent effect in the vasc...
Vasomotor effect of cumulative dose-dependent administration of: PACAP1-38 (a); PACAP1-27 (b); and V...
Vasomotor effect of cumulative dose-dependent administration of: PACAP1-38 (a), PACAP1-27 (b) and VI...
Vasomotor effect of cumulative dose-dependent administration of: PACAP1-38 (a), PACAP1-27 (b) and VI...
Original records show the cumulative dose-dependent effect of PACAP1–38, PACAP1-27 and VIP in the ca...
Upper panel: PACAP and VIP bind to PAC1R/VPAC1R G protein-coupled receptors, and stimulate the cAMP/...
Vasomotor effect of cumulative dose-dependent administration of: Maxadilan (a); Ala11,22,28VIP (b); ...
BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropep...
BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropep...
BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neurope...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
BACKGROUND: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (...
BACKGROUND: PACAP and VIP are closely related neuropeptides with wide distribution and potent effect...
PACAP and VIP are closely related neuropeptides with wide distribution and potent effect in the vasc...
Vasomotor effect of cumulative dose-dependent administration of: PACAP1-38 (a); PACAP1-27 (b); and V...
Vasomotor effect of cumulative dose-dependent administration of: PACAP1-38 (a), PACAP1-27 (b) and VI...
Vasomotor effect of cumulative dose-dependent administration of: PACAP1-38 (a), PACAP1-27 (b) and VI...
Original records show the cumulative dose-dependent effect of PACAP1–38, PACAP1-27 and VIP in the ca...
Upper panel: PACAP and VIP bind to PAC1R/VPAC1R G protein-coupled receptors, and stimulate the cAMP/...
Vasomotor effect of cumulative dose-dependent administration of: Maxadilan (a); Ala11,22,28VIP (b); ...
BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropep...
BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropep...
BACKGROUND: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neurope...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal pept...
BACKGROUND: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (...